Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.37 USD | -2.84% | +5.38% | -30.46% |
Mar. 12 | Ikena Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 12 | North American Morning Briefing : Inflation Data -2- | DJ |
Financials (USD)
Sales 2024 * | 7M | Sales 2025 * | 10.8M | Capitalization | 66.11M |
---|---|---|---|---|---|
Net income 2024 * | -74M | Net income 2025 * | -80M | EV / Sales 2024 * | 9.44 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 6.12 x |
P/E ratio 2024 * |
-0.89
x | P/E ratio 2025 * |
-0.91
x | Employees | 43 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93% |
1 day | -2.84% | ||
1 week | +5.38% | ||
Current month | +3.79% | ||
1 month | +3.79% | ||
3 months | -2.14% | ||
6 months | -66.83% | ||
Current year | -30.46% |
Managers | Title | Age | Since |
---|---|---|---|
Mark Manfredi
FOU | Founder | 53 | 16-01-31 |
Jotin Marango
DFI | Director of Finance/CFO | 45 | 22-04-24 |
Caroline Germa
CTO | Chief Tech/Sci/R&D Officer | 52 | Feb. 28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 67 | 16-02-29 | |
David Bonita
BRD | Director/Board Member | 48 | - |
Director/Board Member | 55 | 20-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - | |
0.00% | 0 M€ | +3.45% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 1.37 | -2.84% | 123,900 |
24-05-07 | 1.41 | +7.63% | 391,991 |
24-05-06 | 1.31 | -0.76% | 235,735 |
24-05-03 | 1.32 | 0.00% | 369,057 |
24-05-02 | 1.32 | +1.54% | 319,175 |
Delayed Quote Nasdaq, May 08, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.46% | 68.04M | |
+22.56% | 46.4B | |
-1.51% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+10.13% | 26.01B | |
-20.44% | 19.52B | |
+26.45% | 12.43B | |
-0.14% | 12.18B | |
-0.47% | 12.13B |
- Stock Market
- Equities
- IKNA Stock